BR9709516A - Emprego de inibidores da troca de na+/h+ celular (nhe) para a preparação de um medicamento para a normalização dos lipídos do soro - Google Patents

Emprego de inibidores da troca de na+/h+ celular (nhe) para a preparação de um medicamento para a normalização dos lipídos do soro

Info

Publication number
BR9709516A
BR9709516A BR9709516A BR9709516A BR9709516A BR 9709516 A BR9709516 A BR 9709516A BR 9709516 A BR9709516 A BR 9709516A BR 9709516 A BR9709516 A BR 9709516A BR 9709516 A BR9709516 A BR 9709516A
Authority
BR
Brazil
Prior art keywords
nhe
medicine
cell
preparation
serum lipids
Prior art date
Application number
BR9709516A
Other languages
English (en)
Inventor
Hans-Willi Jansen
Jan-Robert Schwark
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19712636A external-priority patent/DE19712636A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of BR9709516A publication Critical patent/BR9709516A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
BR9709516A 1996-06-03 1997-05-20 Emprego de inibidores da troca de na+/h+ celular (nhe) para a preparação de um medicamento para a normalização dos lipídos do soro BR9709516A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19622222A DE19622222A1 (de) 1996-06-03 1996-06-03 Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
DE19712636A DE19712636A1 (de) 1997-03-26 1997-03-26 Verwendung von Inhibitoren des zellulären Na+/H+Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
PCT/EP1997/002548 WO1997046226A2 (de) 1996-06-03 1997-05-20 VERWENDUNG VON INHIBITOREN DES ZELLULÄREN Na+/H+-EXCHANGERS (NHE) ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR NORMALISIERUNG DER SERUMLIPIDE

Publications (1)

Publication Number Publication Date
BR9709516A true BR9709516A (pt) 1999-08-10

Family

ID=26026256

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709516A BR9709516A (pt) 1996-06-03 1997-05-20 Emprego de inibidores da troca de na+/h+ celular (nhe) para a preparação de um medicamento para a normalização dos lipídos do soro

Country Status (23)

Country Link
EP (1) EP0918515B1 (pt)
JP (1) JP4527811B2 (pt)
KR (1) KR100511711B1 (pt)
CN (1) CN1221339A (pt)
AR (1) AR007353A1 (pt)
AT (1) ATE293965T1 (pt)
AU (1) AU722166B2 (pt)
BR (1) BR9709516A (pt)
CA (1) CA2257299A1 (pt)
DE (2) DE19622222A1 (pt)
DK (1) DK0918515T3 (pt)
ES (1) ES2241049T3 (pt)
IL (1) IL126935A0 (pt)
NO (1) NO985480L (pt)
NZ (1) NZ333095A (pt)
PL (1) PL189950B1 (pt)
PT (1) PT918515E (pt)
RU (1) RU2211032C2 (pt)
SI (1) SI0918515T1 (pt)
SK (1) SK165898A3 (pt)
TR (1) TR199802505T2 (pt)
WO (1) WO1997046226A2 (pt)
ZA (1) ZA974828B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
DE19859727A1 (de) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
CA2370607A1 (en) 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
DE19945302A1 (de) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
FR2856062B1 (fr) * 2003-06-12 2005-11-11 Aventis Pharma Sa Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
US7230007B2 (en) 2003-06-12 2007-06-12 Sanofi-Aventis Deutschland Gmbh Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
EP2617709B8 (en) * 2003-06-26 2022-12-21 Biotron Limited Guanidine derivatives as antiviral agents
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (en) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US20100256153A1 (en) 2009-03-27 2010-10-07 Bristol-Myers Squibb Company Methods for preventing or reducing risk of mortality
AU2011210765A1 (en) 2010-01-28 2012-09-13 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
EP3552664A1 (en) 2011-05-12 2019-10-16 Proteostasis Therapeutics, Inc. Proteostasis regulators
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
KR20210034039A (ko) 2018-07-19 2021-03-29 아스트라제네카 아베 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110817A (en) * 1988-10-21 1992-05-05 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US4920123A (en) * 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
WO1991012799A1 (en) * 1990-02-28 1991-09-05 The Upjohn Company Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
DK0612723T3 (da) * 1993-02-20 1998-03-30 Hoechst Ag Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IL114670A0 (en) * 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof

Also Published As

Publication number Publication date
AR007353A1 (es) 1999-10-27
IL126935A0 (en) 1999-09-22
EP0918515A2 (de) 1999-06-02
NO985480L (no) 1999-01-28
NZ333095A (en) 2000-08-25
PL330412A1 (en) 1999-05-10
KR20000016240A (ko) 2000-03-25
DE19622222A1 (de) 1997-12-04
NO985480D0 (no) 1998-11-24
RU2211032C2 (ru) 2003-08-27
ES2241049T3 (es) 2005-10-16
JP2000506906A (ja) 2000-06-06
DK0918515T3 (da) 2005-08-15
CA2257299A1 (en) 1997-12-11
AU722166B2 (en) 2000-07-20
WO1997046226A3 (de) 1998-03-05
JP4527811B2 (ja) 2010-08-18
TR199802505T2 (xx) 1999-04-21
WO1997046226A2 (de) 1997-12-11
CN1221339A (zh) 1999-06-30
SI0918515T1 (sl) 2005-12-31
PT918515E (pt) 2005-06-30
AU2957697A (en) 1998-01-05
DE59712287D1 (de) 2005-06-02
EP0918515B1 (de) 2005-04-27
PL189950B1 (pl) 2005-10-31
SK165898A3 (en) 1999-05-07
ATE293965T1 (de) 2005-05-15
KR100511711B1 (ko) 2005-12-26
ZA974828B (en) 1997-12-03

Similar Documents

Publication Publication Date Title
BR9709516A (pt) Emprego de inibidores da troca de na+/h+ celular (nhe) para a preparação de um medicamento para a normalização dos lipídos do soro
PT95729A (pt) Metodo para humidificacao dos tecidos, nomeadamente de celulas epiteliais de mamiferos
MC1782A1 (fr) Preparation pharmaceutique
BR9000153A (pt) Involucro de torax para uso na producao da ventilacao assistida dos pulmoes de um paciente
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
BR9609154A (pt) Uso de linhagens de célula fetais neuro-derivadas para terapia de transplante
ES551858A0 (es) Procedimiento para la preparacion de ligantes de esmalte depositables catodicamente.
MX3886A (es) Procedimiento para la preparacion de compuestos azoicos hidrosolubles
BR8702879A (pt) Permutador de derivacao para transformador
PH22545A (en) Non aromatic fluoroallylamine mao inhibitors
ES555707A0 (es) Procedimiento para la fabricacion de ligantes diluibles con agua, que contienen grupos amino primarios latentes, para lacas cationicas de electroinmersion
PT82926A (pt) Adaptador para lampada fluorescente compacta
HUP0001879A3 (en) Use of inhibitors of the cellular na+/h+ exchanger (nhe) for preparing a medicament for normalizing serum lipids
PT81973B (pt) Processo para a preparacao de inibidores da dopamina-beta-hidroxilase
ES551634A0 (es) Procedimiento para la preparacion de una composicion farmaceutica a base de 3-aminopropoxiindoles
ES540272A0 (es) Sistema de acceso multiple,via radio,para telefonia rural
DK209087D0 (da) Farmaceutisk vandigt gelpraeparat til topisk anvendelse
BR6700322U (pt) Placa para afixacao dos resultados da loteria de numeros(loto)
BR6501734U (pt) Crioextrator para cirurgia de catarata
BR8801604A (pt) Registro de alta pressao para caldeiras
ES285982Y (es) Valvula para llave de paso
BR6500105U (pt) Valvula de quatro vias
BR6600260U (pt) Kit-suporte para aparelhos condicionadores de ar
BR6500086U (pt) Lampada para instrumentos medicos
IT234341Y1 (it) Adattatore portaplacca specialmente per apparecchi da incasso

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.